Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial.
作者信息
Franco Laura, Becattini Cecilia, Vanni Simone, Sbrojavacca Rodolfo, Nitti Cinzia, Manina Giorgia, Masotti Luca, Pomero Fulvio, Cattinelli Sergio, Cappelli Roberto, Re Roberta, Agnelli Giancarlo
机构信息
Vascular Emergency Medicine-Stroke Unit, University of Perugia, Perugia, Italy.
Department of Emergency Medicine, "Careggi" University Hospital, Florence, Italy.
出版信息
Blood Transfus. 2018 Jul;16(4):387-391. doi: 10.2450/2017.0335-16. Epub 2017 Mar 15.
Abstract
摘要
相似文献
1
Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial.口服抗凝剂相关的临床相关非大出血：非大出血可能并非微不足道。
Blood Transfus. 2018 Jul;16(4):387-391. doi: 10.2450/2017.0335-16. Epub 2017 Mar 15.
2
Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients. A retrospective propensity score matched cohort study.老年非瓣膜性心房颤动患者口服抗凝剂的不同安全性概况。一项回顾性倾向评分匹配队列研究。
Int J Cardiol. 2018 Aug 15;265:103-107. doi: 10.1016/j.ijcard.2018.04.117. Epub 2018 Apr 25.
3
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.一项全国性注册研究，旨在比较服用口服抗凝剂的心房颤动患者的出血率。
Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):28-36. doi: 10.1093/ehjcvp/pvw031. Epub 2016 Sep 27.
4
Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making.在当代实践中，使用口服抗凝剂治疗的心房颤动患者的长期卒中与出血风险：为共同决策提供证据。
Int J Cardiol. 2017 Oct 15;245:174-177. doi: 10.1016/j.ijcard.2017.07.043. Epub 2017 Jul 14.
5
Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation.直接口服抗凝剂的使用与高龄房颤患者的出血发生率
J Thromb Thrombolysis. 2016 Nov;42(4):573-8. doi: 10.1007/s11239-016-1410-z.
6
Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).在临床实践中，非维生素K拮抗剂口服抗凝剂与华法林治疗心房颤动患者大出血的管理比较（来自心房颤动更明智治疗结果登记处[ORBIT-AF II]的第二阶段）
Am J Cardiol. 2017 May 15;119(10):1590-1595. doi: 10.1016/j.amjcard.2017.02.015. Epub 2017 Mar 28.
7
Assessment of risk factors for bleeding in Japanese patients with non-valvular atrial fibrillation receiving warfarin treatment: A subanalysis of the J-RHYTHM Registry.日本非瓣膜性心房颤动患者接受华法林治疗时出血危险因素的评估：J-RHYTHM注册研究的亚分析
Int J Cardiol. 2015 Dec 15;201:308-10. doi: 10.1016/j.ijcard.2015.08.059. Epub 2015 Aug 5.
8
The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.心房颤动患者中4种直接口服抗凝剂不适当低剂量使用情况的比较：来自单中心注册数据库
J Stroke Cerebrovasc Dis. 2018 Nov;27(11):3280-3288. doi: 10.1016/j.jstrokecerebrovasdis.2018.07.028. Epub 2018 Aug 16.
9
Bleeding risks with novel oral anticoagulants during catheter ablation of atrial fibrillation: a systematic review and network meta-analysis.新型口服抗凝药在心房颤动导管消融术中的出血风险：一项系统评价和网状Meta分析
J Interv Card Electrophysiol. 2015 Nov;44(2):105-11. doi: 10.1007/s10840-015-0053-x. Epub 2015 Sep 5.
10
Comparison of Bleeding Risk Scores in Patients With Nonvalvular Atrial Fibrillation Starting Direct Oral Anticoagulants.开始使用直接口服抗凝剂的非瓣膜性心房颤动患者出血风险评分的比较
Rev Esp Cardiol (Engl Ed). 2017 Oct;70(10):878-880. doi: 10.1016/j.rec.2017.01.021. Epub 2017 Feb 24.
引用本文的文献
1
Once- versus twice-daily direct oral anticoagulants after ischemic stroke in atrial fibrillation - A post-hoc analysis of the ELAN trial.心房颤动缺血性卒中后每日一次与每日两次直接口服抗凝剂治疗——ELAN试验的事后分析
Eur Stroke J. 2025 Aug 11:23969873251360974. doi: 10.1177/23969873251360974.
2
Frailty and Atrial Fibrillation: A Closer Look at the FRAIL-AF Trial.衰弱与心房颤动：深入剖析FRAIL-AF试验
Arq Bras Cardiol. 2024 Jun 17;121(5):e20230671. doi: 10.36660/abc.20230671. eCollection 2024.
3
Qualitative experiences, values, and decisional needs of patients with unprovoked venous thromboembolism who suffer bleeding-"This pill will keep you alive tonight".发生出血的不明原因静脉血栓栓塞症患者的定性体验、价值观和决策需求——“这片药能让你活到今晚”
Res Pract Thromb Haemost. 2024 Mar 1;8(2):102360. doi: 10.1016/j.rpth.2024.102360. eCollection 2024 Feb.
4
Outcomes of venous thromboembolism in patients with inherited thrombophilia treated with direct oral anticoagulants: insights from the RIETE registry.遗传性血栓形成倾向患者接受直接口服抗凝剂治疗后的静脉血栓栓塞结局：来自 RIETE 登记研究的见解。
J Thromb Thrombolysis. 2024 Apr;57(4):710-720. doi: 10.1007/s11239-024-02957-4. Epub 2024 Mar 16.
5
Balancing risks of recurrent venous thromboembolism and bleeding with extended anticoagulation: a decision analysis.延长抗凝治疗中复发性静脉血栓栓塞与出血风险的平衡：一项决策分析
Res Pract Thromb Haemost. 2023 Nov 26;8(1):102274. doi: 10.1016/j.rpth.2023.102274. eCollection 2024 Jan.
6
Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolism.老年急性静脉血栓栓塞症患者出血事件的发生率及临床影响。
Blood Adv. 2023 Jan 24;7(2):205-213. doi: 10.1182/bloodadvances.2022007263.
7
Serial use of existing clinical decisions aids can reduce computed tomography pulmonary angiography for pulmonary embolism.连续使用现有的临床决策辅助工具可以减少肺栓塞的计算机断层肺动脉造影。
Intern Emerg Med. 2021 Nov;16(8):2251-2259. doi: 10.1007/s11739-021-02703-1. Epub 2021 Mar 20.
8
Impact of pharmacist-conducted anticoagulation patient education and telephone follow-up on transitions of care: a randomized controlled trial.药师主导的抗凝患者教育和电话随访对过渡期护理的影响：一项随机对照试验。
BMC Health Serv Res. 2021 Feb 16;21(1):151. doi: 10.1186/s12913-021-06156-2.
9
A Review of the Incidence Diagnosis and Treatment of Spontaneous Hemorrhage in Patients Treated with Direct Oral Anticoagulants.直接口服抗凝剂治疗患者自发性出血的发生率、诊断与治疗综述
J Clin Med. 2020 Sep 15;9(9):2984. doi: 10.3390/jcm9092984.
10
Thirty-day mortality in atrial fibrillation patients with gastrointestinal bleeding in the emergency department: differences between direct oral anticoagulant and warfarin users.急诊科房颤合并胃肠道出血患者 30 天死亡率：直接口服抗凝剂与华法林使用者之间的差异。
Intern Emerg Med. 2020 Mar;15(2):311-318. doi: 10.1007/s11739-019-02229-7. Epub 2019 Nov 21.
本文引用的文献
1
Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.在 AMPLIFY 试验中，观察到接受阿哌沙班或依诺肝素及华法林治疗的静脉血栓栓塞患者出血事件的临床表现和病程。
Thromb Haemost. 2016 Nov 30;116(6):1159-1164. doi: 10.1160/TH16-02-0137. Epub 2016 Sep 1.
2
Safety and efficacy of oral factor-Xa inhibitors versus Vitamin K antagonist in patients with non-valvular atrial fibrillation: Meta-analysis of phase II and III randomized controlled trials.口服Xa因子抑制剂与维生素K拮抗剂治疗非瓣膜性心房颤动患者的安全性和有效性：II期和III期随机对照试验的荟萃分析
Int J Cardiol. 2016 Sep 1;218:235-239. doi: 10.1016/j.ijcard.2016.05.059. Epub 2016 May 14.
3
Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.非手术患者心房颤动和静脉血栓栓塞性疾病抗凝剂研究中临床相关非大出血的定义：国际血栓与止血学会科学与标准化委员会的沟通
J Thromb Haemost. 2015 Nov;13(11):2119-26. doi: 10.1111/jth.13140.
4
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.XANTUS：一项关于利伐沙班用于预防心房颤动患者中风的真实世界、前瞻性观察性研究。
Eur Heart J. 2016 Apr 7;37(14):1145-53. doi: 10.1093/eurheartj/ehv466. Epub 2015 Sep 1.
5
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.日常护理中利伐沙班出血的发生率、管理及结局：德累斯顿新型口服抗凝药登记研究结果
Blood. 2014 Aug 7;124(6):955-62. doi: 10.1182/blood-2014-03-563577. Epub 2014 May 23.
6
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.新型口服抗凝剂与维生素 K 拮抗剂治疗急性有症状静脉血栓栓塞症的有效性和安全性：系统评价和荟萃分析。
J Thromb Haemost. 2014;12(3):320-8. doi: 10.1111/jth.12485.
7
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.新型口服抗凝剂与华法林治疗心房颤动患者的疗效和安全性比较：随机试验的荟萃分析。
Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.
8
Edoxaban versus warfarin in patients with atrial fibrillation.依度沙班与华法林用于房颤患者。
N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.
9
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.依度沙班与华法林治疗有症状的静脉血栓栓塞症。
N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31.
10
Oral apixaban for the treatment of acute venous thromboembolism.口服阿哌沙班治疗急性静脉血栓栓塞症。
N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1.
Zotero 插件